Micronutrients and Benefits of Supplementation for Reducing the Risk of Progression of Age-related Macular Degeneration – An Update

Maurizio Battaglia Parodi, Maria Rosaria Mollo, Andrea Brunoro, Alessandro Arrigo and Francesco Romano

1. Ophthalmology Department, Vita-Salute San Raffaele University, Milan, Italy; 2. Bausch & Lomb IOM spa, Milan, Italy

DOI: https://doi.org/10.17925/ECR.2018.12.1.39

Age-related macular degeneration (AMD) is a chronic, progressive degenerative disease associated with reduction in visual acuity. Preventive and supportive strategies to slow progression of the disease are of primary importance. Oxidative stress contributes substantially to macular degeneration and is related to cellular damage caused by reactive oxygen species. Retinal structures, in fact, are susceptible to oxidative damage, which can be influenced by insufficient dietary intake of antioxidants. Oral vitamin and mineral supplementation (especially vitamins C and E, lutein, zeaxanthin, zinc, and omega-3 fatty acids) has been widely investigated for its role in helping to slow disease progression. There is now general consensus that the AREDS1 and AREDS2 formulations exert their positive effects via antioxidant properties, and considering their potential benefits, commercially-available dietary supplements are now available based on the AREDS studies. Indeed, the AREDS2 formulation with 10 mg lutein/day and 2 mg zeaxanthin/day can be considered as standard of care to reduce the probability of advanced AMD in patients at high risk for progression to severe visual loss. Dietary supplements may help to delay the onset of AMD, and potentially progression of the disease. Clinicians caring for patients with AMD should be aware of the benefits of oral supplements for AMD.

Keywords
Age-related macular degeneration, lutein, zeaxanthin, DHA, carotenoids, vitamin C, vitamin E, omega-3 fatty acids, supplementation, prevention

Disclosures: Maria Rosaria Mollo and Andrea Brunoro are employees of Bausch & Lomb. Maurizio Battaglia Parodi, Alessandro Arrigo and Francesco Romano have nothing to disclose.


Compliance with Ethics: This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. © The Authors 2018

Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.

Received: 11 June 2018

Accepted: 23 July 2018

Citation: European Ophthalmic Review, 2018;12(1):39–44

Corresponding Author: Maurizio Battaglia Parodi, Department of Ophthalmology Vita-Salute University, Ospedale San Raffaele, Via Olgietrina 60, 20132, Milan, Italy. E: mbasp@vlab.it

Support: The publication of this article was supported by Bausch & Lomb.

Pathogenesis of age-related macular degeneration

The exact pathogenesis of AMD is not completely understood, despite progress in knowledge of the disease and its underlying mechanisms. Current hypotheses regarding its pathogenesis involve an interplay of complex multifactorial interactions of several factors, including metabolic, genetic and environmental factors. As for many other diseases, oxidation, inflammation and angiogenesis in the retinal pigment epithelium (RPE) are held to have crucial roles in the pathogenesis of AMD. Impaired function of the RPE is involved in the majority of theories about the pathogenesis of AMD. The RPE is composed of a layer of highly specialised cells that have a number of functions...
Table 1: Clinical classification for age-related macular degeneration

<table>
<thead>
<tr>
<th>Classification of AMD</th>
<th>Definition (lesions assessed within two disc diameters of fovea in either eye)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No apparent aging changes</td>
<td>No drusen and no AMD pigmentary abnormalities*</td>
</tr>
<tr>
<td>Normal aging changes</td>
<td>Only drusenoids (small drusen ≤63 µm) and no AMD pigmentary abnormalities*</td>
</tr>
<tr>
<td>Early AMD</td>
<td>Medium drusen (&gt;63 µm and ≤125 µm) and no AMD pigmentary abnormalities*</td>
</tr>
<tr>
<td>Intermediate AMD</td>
<td>Large drusen &gt;125 µm and/or any AMD pigmentary abnormalities*</td>
</tr>
<tr>
<td>Late AMD</td>
<td>Neovascular AMD and/or any geographic atrophy</td>
</tr>
</tbody>
</table>

*AMD pigmentary abnormalities = any definite hyper- or hypopigmentary abnormalities associated with medium or large drusen but not associated with known disease entities. AMD = age-related macular degeneration. Reproduced with permission from Ferris et al., 2013.

aimed to support and sustain the survival of photoreceptor cells as well as to allow the exchange of nourished and metabolic wastes. Indeed, the photoreceptor layer has high metabolic activity, thus requiring a large amount of nutritional needs and biological clearance of photoreceptor debris, functions that are aided by the RPE. Therefore, even if a specific insult leading to damage of the RPE has not been found, it is clear that it can be affected by many factors such as the levels of certain nutrients and immune damage. It is for this reason that damage to the RPE may be worsened by extrinsic factors such as smoking.

Complement is an aspect of the innate immune system that is also clearly involved in the pathology of AMD. In this regard, defects in complement system genes have been shown to predispose individuals to AMD, and many common (e.g., CFH, C2/CFB, C3, and CFI) and less common (e.g., C2/CFB, C3, C9, CFH, CFI, and VTN) genetic variants have been modified. It is thought that complement produces autoimmune-mediated retinal damage, which can help to establish a sustained inflammatory response that leads to retinal damage.

Considering the pathophysiology of AMD, the early changes of AMD often start with drusen formation in the macular area; drusen are tiny yellowish accumulations of extracellular material, lipids, amyloid, complement factors and cellular debris that build up between Bruch’s membrane and the RPE. These deposits may be related to failure of the RPE to process cellular debris associated with outer segment turnover. AMD is believed to progress along a continuum, starting from drusen formation up to the atrophic changes typical of dry AMD, the choroidal neovascularisation characterising wet AMD, being considered a step toward a more global atrophic degeneration, especially after choroidal neovascularisation characterising wet AMD, being considered a step toward a more global atrophic degeneration, especially after anti-VEGF treatment. The manifestation of drusen is associated with several processes which include thickening of the collagenous layers of Bruch’s membrane, deterioration of elastin and collagen within Bruch’s membrane, augmented advanced glycation end products, and accumulation of both lipids and exogenous proteins. Such alterations may act as a physical barrier to passage of fluid and nutrients between the choroid and outer retina resulting in relative ischemia, leading to further deterioration. Early AMD is usually asymptomatic and is clinically defined by accumulation of medium-sized drusen (63–125 µm), and accompanied by pigmentary abnormalities (Table 1).

In roughly 10–15% of patients with dry AMD, the deterioration will become more extensive and accompanied by significant vision loss due to geographic atrophy, progressing to the wet form. As AMD progresses, there is a gradually increased loss of RPE and photoreceptor cells. Progression to wet AMD implies that fluid, exudates and/or blood are present between the neural retina and the RPE and/or, as in the case of detachment of the RPE, between the RPE and Bruch’s membrane. Patients will experience gradual loss of visual function over a time span of many years. Larger drusen (>125 µm) are present in intermediate and advanced forms of AMD (Table 1). If the condition is not treated, AMD advances further to a scarring stage over the course of over several months and years.

Retinal pigment epithelium and oxidative stress
Without a doubt, oxidative stress is a substantial contributor to macular degeneration, and is related to cellular damage caused by reactive oxygen species (ROS). ROS include a range of compounds that comprise free radicals and many by-products of oxygen metabolism. During aging, the production of free radicals increases, an event that is associated with progressive damage to cellular structures. The RPE, as with other structures, are susceptible to damage by oxidative stress, and is highly influenced by an inadequate dietary intake of antioxidants. Damage to the RPE leads to accumulation of proinflammatory substances in addition to molecules that generate additional ROS and, consequently, additional oxidative stress, further damaging the RPE and establishing a sort of vicious circle. Drusen, in fact, contain several of these products, such as lipofuscin, which is accumulated in RPE. Lipofuscin, a mixture rich in lipid-protein complexes, contains by-products of vitamin A metabolism and lipid peroxidation.

Of interest, the existence of endogenous defence mechanisms can help to counteract the negative effects of ROS. The endogenous antioxidant network includes several vitamins (C and E), carotenoids (carotenes, lycopene, lutein and zeaxanthin) and several other compounds with antioxidant activity such as flavonoids, uric acid, and coenzyme Q10. Such antioxidant molecules can have protective effects against damage caused by free radicals. In the eye and retina, vitamins C and E along with lutein and zeaxanthin appear to be the most relevant. This highlights the importance of adequate dietary intake of these micronutrients. While in most settings, normal dietary intake is adequate, this however varies among countries and individual dietary consumption. Moreover, lutein and zeaxanthin are not synthesised by humans and are found in some fruits and vegetables like broccoli, lettuce and spinach. This then raises the possibility that dietary supplementation may be of benefit in preventing or slowing progression of AMD. Indeed, several types of compounds have been studied in terms of a potential role in protection of AMD: antioxidant vitamins (mainly C and E), carotenoids and omega-3 fatty acids. The most relevant results on these factors are summarized below, whereas the main studies assessing supplementation and/or dietary intake of vitamins and antioxidants are listed in Table 2.

Micronutrients and age-related macular degeneration
Vitamins C and E
As humans do not have the ability to synthesise vitamin C, it can be considered as an essential nutrient; it is perhaps the most important...
Nutritional Supplementation for Prevention of AMD

Table 2: Main studies on supplementation intake and age-related macular degeneration

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of supplementation assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Eye Disease Case-Control Study (2004)</td>
<td>Carotenoids and vitamins A, C, and E</td>
</tr>
<tr>
<td>Cho et al., 2004 (21)</td>
<td>Only drupelets (small drusen ≤3 μm) and no AMD pigmentary abnormalities*</td>
</tr>
<tr>
<td>Early AMD</td>
<td>Antioxidant vitamins and carotenoids</td>
</tr>
<tr>
<td>Christen et al., 1999 (22)</td>
<td>Vitamins C, E or multivitamins</td>
</tr>
<tr>
<td>The Pathologies Oculaires Liées à l’Age (POLA) Study (23)</td>
<td>Vitamins A, E, and C</td>
</tr>
<tr>
<td>The Blue Mountains Eye Study (24)</td>
<td>Carotene, vitamin C, retinol, and zinc</td>
</tr>
<tr>
<td>The Beaver Dam Eye Study (25)</td>
<td>Pro-vitamin A carotenoids, vitamin C, vitamin E, zinc</td>
</tr>
<tr>
<td>West et al., 1993 (26)</td>
<td>Retinol, ascorbic acid, alpha-tocopherol, and beta-carotene</td>
</tr>
<tr>
<td>Cochrane reviews (27-29)</td>
<td>Carotenoids, vitamins C and E and minerals (selenium and zinc)</td>
</tr>
<tr>
<td>Mares-Perlman et al., 1996 (30)</td>
<td>Pro-vitamin A carotenoids, vitamin C, vitamin E, zinc</td>
</tr>
<tr>
<td>Liu et al., 2014 (31)</td>
<td>Lutein and zeaxanthin</td>
</tr>
<tr>
<td>The Veterans LAST study (Lutein Antioxidant</td>
<td>Lutein, antioxidant vitamins, minerals</td>
</tr>
<tr>
<td>Supplementation Trial) (32)</td>
<td></td>
</tr>
<tr>
<td>Weigert et al., 2011 (33)</td>
<td>Lutein</td>
</tr>
<tr>
<td>Ma et al., 2012 (34)</td>
<td>Lutein and zeaxanthin</td>
</tr>
<tr>
<td>Age-Related Eye Disease Study 1 (35)</td>
<td>Vitamins C and E, beta carotene, and zinc</td>
</tr>
<tr>
<td>Age-Related Eye Disease Study 2 (36)</td>
<td>Vitamins C and E, beta carotene, zinc, lutein, zeaxanthin, docosahexaenoic + eicosapentaenoic acids</td>
</tr>
</tbody>
</table>

AMO = age-related macular degeneration.

soluble antioxidant given its effects on the reduction of ROS. Vitamin C has long been held to be protective in age-related retinal disease, even if epidemiological data on the relationship between dietary intake of vitamin C and the risk of AMD are not entirely consistent. Earlier studies, such as The Eye Disease Control Study, reported that a lower risk for AMD was suggested among subjects with higher intake of vitamin C. However, these results were not entirely confirmed in later studies, such as The Eye Disease Control Study, reported that a lower risk for AMD was suggested among subjects with higher intake of vitamin C. Moreover, these results were not entirely confirmed in later studies where no unambiguous association was found between vitamin C and risk of developing AMD. Three Cochrane analyses have failed to find clear clinical evidence for vitamin C in prevention of AMD when administered alone. Notwithstanding its role as an important antioxidant, additional studies are needed to fully understand the potential role of vitamin C in AMD. In fact, a potential role for vitamin C in AMD may be difficult to demonstrate when administered alone, and it is entirely possible that this antioxidant may also act in concert with other antioxidants.

Vitamin E is a fat-soluble vitamin and an effective scavenger of free radicals; vitamin E supplements usually contain α-tocopherol or a mixture of other forms of vitamin E. In contrast with vitamin C, the evidence for the benefits of vitamin E supplementation in AMD is based on several lines of well-established evidence. This is due firstly to the fact that photoreceptors and the RPE likely have the highest concentrations of vitamin E among all tissues. Moreover, retinal levels of vitamin E are highest in the retina, and can protect the macular region from phototoxic injury. The carotenoids lutein and zeaxanthin also have a significant biological role in prevention and slow the progression of AMD. Data from the The Age-Related Eye Disease Study (AREDS2) study (discussed below) appear to confirm that such a relation is possible, even if the exact degree to which and at which stage the greatest benefits are seen is not clear at present. Prior to the AREDS study results, several interventional studies provided data for a beneficial effect of lutein and zeaxanthin in retinal disease. Most investigations have indicated that macular pigment has also been shown to improve following a healthier diet. Several studies have indicated that, indeed, there is an association between reduced dietary intake of lutein/zeaxanthin and the development of AMD. Data from the The Age-Related Eye Disease Study (AREDS2) study (discussed below) appear to confirm that such a relation is possible, even if the exact degree to which and at which stage the greatest benefits are seen is not clear at present. Prior to the AREDS study results, several interventional studies provided data for a beneficial effect of lutein and zeaxanthin in retinal disease. Most investigations have indicated that macular pigment optical density can be increased with lutein supplementation. In particular, a recent study by Ma et al. reported that supplementation with lutein and zeaxanthin in patients with early AMD improved macular pigment optical density as well as visual function. In addition, the PIMAVOSA trial reported that there was significant correlation between macular pigment optical density and plasma levels of both lutein and...
Macular Degeneration

Some of the apparently conflicting results in the literature may be explained if such supplements are effective only when dietary intake is below a sufficient threshold. A Cochrane review from 2017 concluded that there is 'no evidence' for supplements such as lutein and zeaxanthin. As such, larger trials are warranted to further define its precise role in AMD and identify those individuals who will benefit most from supplementation with lutein and zeaxanthin.

Zinc

Zinc ions have been implicated in the regeneration of rhodopsin and in the phototransduction cascade in photoreceptors; zinc is also a cofactor for several ocular enzymes involved in oxidative processes such as superoxide dismutase and catalase. Only a very limited number of trials have attempted to study the potential role of orally supplemented zinc on AMD in the absence of other supplements. In 2013, a systematic review of trials with zinc was published, which included 10 studies, with the main conclusion that the effect of zinc intake was inconclusive in prevention of AMD. However, the AREDS1 trial demonstrated that 80 mg zinc oxide, alone or combined with antioxidants, showed a significant reduction in the risk of progression to advanced AMD in patients with moderate AMD, even if the difference in loss of visual acuity was not statistically significant. Another randomised trial reported a significant increase in visual acuity in early AMD patients, although a second study documented no significant effects of zinc on visual acuity in advanced AMD. Based primarily on the above studies, it is current opinion that zinc treatment may be effective in preventing progression to advanced AMD, even if it is likely that zinc supplementation by itself may not be adequate to produce clinically meaningful differences in visual acuity.

Omega-3 fatty acids

Both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are considered essential dietary compounds. The omega-3 fatty acids EPA and DHA are clearly implicated in AMD, and the clinical data establishing a link between insufficient intake of omega-3 fatty acids and AMD are relatively strong. The Blue Mountains Eye Study reported a relation between higher frequency of fish intake and a decreased lower risk of late AMD. Individuals with the highest intake of omega-3 fatty acids showed a reduced risk of early AMD versus those with the lowest intake (odds ratio 0.41). In particular, consumption of fish at least once a week was associated with 40% reduction of early age-related maculopathy, and consumption at least three times per week was furthermore associated with a reduced incidence of late age-related maculopathy (odds ratio 0.25). In a 10-year extension of the same study, fish consumption once a week reduced the risk of neovascular AMD by about one-half versus consumption less than once per week (odds ratio 0.47, p=0.002).

Other studies have also found a relation between consumption of omega-3 fatty acid and a reduced risk of neovascular AMD. The European Eye Study (EUREYE) was a cross-sectional population-based study that investigated dietary intake of DHA and EPA in 105 patients with AMD and 2,170 controls. This study found that consumption of DHA or EPA led to a reduced risk of neovascular AMD (odds ratio 0.32; p=0.03 and odds ratio 0.29, p=0.02, respectively). In addition, consumption of oily fish at least once per week reduced the risk of neovascular AMD by about one-half versus consumption less than once per week (odds ratio 0.47, p=0.002).

In AREDS2, the addition of DHA + EPA to the prior AREDS formulation did not further reduce the calculated risk of AMD, an unexpected finding considering previous epidemiological studies. However, differences among trials may be due to a number of factors, including differences in formulations used or variations in consumption of fish. Considering the available evidence for omega-3 fatty acids, it is nonetheless reasonable to promote the consumption of dietary fatty fish in patients with AMD.

Nutritional supplements in therapeutic approach to dry age-related macular degeneration

The Age-Related Eye Disease Study

AREDS was a landmark clinical trial sponsored by the US National Eye Institute to evaluate the effect of high doses of vitamin C, vitamin E, beta-carotene, and zinc on the progression of AMD and cataract. From 1992–1998, AREDS1 enrolled 3,640 patients aged 55–80 years with a diagnosis of AMD. The supplementation given in AREDS1 contained vitamin C (500 mg), vitamin E (273 mg/400 IU), beta-carotene (15 mg), zinc (80 mg), and copper (2 mg). AREDS1 showed that there was a significant benefit of antioxidants in combination with zinc, which was associated with a reduced risk of progression to AMD by 28% (odds ratio 0.72; 99% confidence interval = 0.52–0.98) after a mean follow-up of 6.3 years in individuals >55 years of age. Shortly thereafter, the AREDS formulation became part of standard of care. Due to serious concerns about the possibility that beta-carotene might increase the risk of lung cancer in current or former smokers, this compound was replaced by lutein/zeaxanthin in AREDS2.

The Age-Related Eye Disease Study 2

The primary aim of AREDS2 was to evaluate the efficacy of lutein/zeaxanthin and/or omega-3 long-chain polyunsaturated fatty acids...
Nutritional Supplementation for Prevention of AMD

Acid supplementation in reducing the risk of developing advanced AMD. In AREDS2, the amount of zinc was reduced and beta-carotene was omitted from the formulation. Differences in the composition of the AREDS1 and AREDS2 formulations are shown in Table 3. Primary randomisation was to one of four groups: placebo, lutein/zeaxanthin, DHA/EPA, or a combination of the latter two. Secondary randomisation included the original AREDS1 medication, the AREDS1 formulation without beta-carotene, the AREDS1 formulation with reduced zinc, or the AREDS1 formulation without beta-carotene and low zinc. Median follow-up was 5 years, and the study included 4,203 participants aged 50–85 years who were at risk for progression to advanced AMD. Comparison with placebo in the primary analyses showed no significant reduction in progression to advanced AMD, with no apparent effect of beta-carotene elimination or lower-dose zinc on progression to advanced AMD. However, an excess of lung cancers was observed in the beta-carotene versus no beta-carotene group (p=0.04), which were mostly in former smokers. Secondary analyses confirmed that lutein/zeaxanthin was more appropriate than beta-carotene in the AREDS-type supplements. Nonetheless, evaluation of the main effects of lutein/zeaxanthin in the entire study cohort that received the lutein/zeaxanthin supplement compared with the cohort that did not receive lutein/zeaxanthin showed a significant reduction of progression to advanced AMD (p<0.05), confirming the overall benefit and rationale for an AREDS-type formulation in AMD. The AREDS2 study, however, has a number of limitations including its complex randomisation scheme with numerous subgroups, which could have resulted in the lack of statistical power needed to confirm its primary endpoint.

The role of dietary supplements in age-related macular degeneration

There is general agreement that both the AREDS1 and the AREDS2 formulations exert their positive effects via antioxidant properties. The available evidence shows that all AMD patients should be given advice to increase the consumption of green leafy vegetables and to eat fatty fish, at least twice a week. A Mediterranean type diet may also provide additional benefits in other age-related diseases that go well beyond AMD.

Given its potential benefits, it is unsurprising that a wide number of commercially-available dietary supplements are based on, or make reference, to the AREDS studies. These include those which include, but are not limited to, the compounds present in the original or second AREDS2 formulation (e.g., Centrum Silver®, Pfizer, New York, NY, US) as well as those specifically dedicated to age-related eye diseases with additional supplements (e.g., PreserVision®, Bausch & Lomb Incorporated, Rochester, NY, US). Such formulations may be particularly beneficial for individuals, such as the elderly, who cannot achieve the necessary levels of these micronutrients with diet alone. The AREDS2 formulation with 10 mg lutein/day and 2 mg zeaxanthin/day can now be considered as the standard of care for reducing the probability of advanced AMD in patients with substantial risk factors for progression to severe visual loss, and there is evidence that subjects receiving AREDS2-type supplements might have stabilisation and improvement of best-corrected visual acuity.

It is current consensus that patients with moderate or advanced AMD should be advised to use AREDS-based supplements, while current or ex-smokers are advised to avoid formulations with beta-carotene. This is also considered sound advice given the overall favourable safety profile and lack of side effects observed with the AREDS formulations. These dietary modifications may provide the opportunity to delay the onset of AMD, and perhaps progression of the disease. However, there is less consensus on the effects that AREDS-based supplementation may have on prevention of AMD.

The oral supplements proposed have several advantages. In particular, supplements are readily-available and do not require a prescription. Moreover, a nutritional supplement based on the AREDS2 formulation is not known to have any adverse effects. Taken together, if recommended by experts in AMD, patients are likely to show high levels of compliance with the formulation. This latter point is especially important, and ophthalmologists and other healthcare providers caring for patients with AMD should be aware of the importance that their advice is likely to have regarding the benefits of oral for AMD.

Adherence to supplementation in patients with age-related macular degeneration

In spite of the potential positive effects on public health, a variable adherence to the use of the supplementation in patients with AMD has been repeatedly described. More specifically the available studies have reported an adherence to AREDS recommendations ranging from 36–88%. Failure to comply with AREDS recommendations may be ascribed to a number of reasons including the lack of awareness of the importance of supplementation in prevention of AMD, the poor collaboration with ophthalmologists regarding the nutritional support, the fear of potential interactions with other medicine, and the additional cost of antioxidant supplementation. Interestingly the rate of adherence tends to reduce in proportion to the increase of patients’ age and duration of the disease, since just 38% of patients over 80 were taking supplementation compared with 45% of patients aged 50–65. Moreover, the rate of adherence was reported to be 41% during the first year of therapy, reducing to 36% after the third year. Patient education seems essential in the attempt to reduce all the modifiable AMD risk factors, especially regarding supplementation. Intensive patient education including a policy of providing verbal and written instructions along with verbal repetition of these instructions from each staff member on each patient visit could double the adherence to supplementation. To increase the patient adherence, it may be hypothesised that the use of a nutritional oral supplement in oorodispensable microgranules, instead of tablets, would improve the assumption. Indeed, the size of tablets, even when small, are not so easy to swallow, which is relevant is certain patient populations, especially the elderly. Overall, ophthalmologists should stress the importance of nutritional supplementation in AMD patients in order to implement the awareness of the role of nutrition in AMD.

Review

Macular Degeneration


51. Weaver IT, Beaumont FE. The effect of intensive education on concordance with the Age-Related Eye Disease Study (AREDS) recommendations in a tertiary referral practice. Ophthalmologica. 2015;238:61–5.